Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
Immune cells called microglia can completely repopulate themselves in the retina after being nearly eliminated, according to a new study in mice from scientists at the National Eye Institute (NEI).
A competition for radical ideas in the fight against blindness will move to its next phase by challenging participants to build functioning human retina prototypes.
The recent approval of two novel medications for glaucoma – the first new medications for the disorder in nearly 18 years – are fruit borne from decades of foundational scientific research supported by the National Eye Institute (NEI).
Common, unavoidable eye movements may be a cause of glaucoma in people with normal intraocular pressure (normal-tension glaucoma), according to new research supported by the National Eye Institute.
In a major step forward in the battle against macular degeneration, researchers at the University of Virginia School of Medicine have discovered a critical trigger for the damaging inflammation that ultimately robs millions of their sight.
A protein shaped like a 'Y' made NEI-funded scientists at Georgia Tech do a double-take may change the way they think about the protein which is sometimes implicated in glaucoma.
NIH scientists have simplified manufacturing and dosing of a potential drug candidate for the autoimmune eye disease uveitis—a vision-threatening condition that accounts for about 15 percent of blindness in the U.S.
A new study by NEI-funded researchers at The Ohio State University suggests that farsighted preschoolers and kindergartners have a harder time paying attention and that could put them at risk of slipping behind in school.
A proposal to create a living model of the human retina, the light-sensitive tissue at the back of the eye, won $90,000 in the National Eye Institute (NEI) 3-D Retina Organoid Challenge (3-D ROC).